Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2020-09-16 Director's Dealing
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-09-16 English
FORM 4 SUBMISSION
Director's Dealing
2020-09-16 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes a material definitive agreement amendment related to a loan and security agreement with Silicon Valley Bank, including borrowing terms and financial obligations. There are no financial statements or detailed financial performance data presented, only a description of the amendment and related obligations. The document is not an annual or quarterly report, earnings release, or management discussion. It is a regulatory filing announcing a material event related to financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4694 characters, which is sufficient to contain substantive information about the financing update rather than just a brief announcement or certification.
2020-09-03 English
10-Q
Interim / Quarterly Report Q2 2020
2020-08-07 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2020, by Mersana Therapeutics, Inc. It announces the issuance of a press release regarding financial results for the second quarter ended June 30, 2020. The text explicitly states that the press release is furnished as an exhibit and that the information is being furnished, not filed, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 3892 characters, which is relatively short and consistent with an 8-K filing announcing earnings results. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Therefore, the correct classification is ER with high confidence.
2020-08-07 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-10 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.